The International Myeloma Working Group [82] and the European myeloma network [83] state that the minimum testing required is determination of TP53 deletion and presence of a t(4;14)(p16;q32);FGFR3/MMSET-IGH gene rearrangement. Here, NSD2 is linked to plasma cell myeloma.